1. Scrip
  2. >>New Products

Intercept Unlikely To Refile OCA For NASH Before Late 2021

 
• By Joseph Haas

Once determined to resubmit its NDA by the end of 2020, Intercept now says talks with the FDA have presented a new path to approval in non-alcoholic steatohepatitis that could mean refiling sometime in 2021.

Binocular viewer_1200X675
Intercept can see a path forward in NASH, but it will take a while

Intercept Pharmaceuticals, Inc.’s announcement that it hopes to refile the new drug application for obeticholic acid, its non-alcoholic steatohepatitis drug candidate, sometime in 2021 dramatically changes the timeline for the drug’s potential approval, but investors responded positively to the news, perhaps indicating relief that a clear path to approval now seems to be in place.

During the company’s third quarter earnings call on 9 November, CEO Mark Pruzanski said a type A end-of-review meeting with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from Scrip